ArticleNanomedicine (London, England)2025
Topical delivery of pterostilbene nanoemulgel ameliorates imiquimod-induced psoriasis-like skin inflammation in mice.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhanced Skin Delivery of Mussel Adhesive Protein Modified Pluronic F127 Micelles Loaded with Curcumin for Effective Topical Treatment of Psoriasis.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study evaluates the therapeutic potential of Pterostilbene (PTN), a natural stilbenoid, in an imiquimod (IMQ)-induced psoriasis model. Due to PTN's poor solubility and bioavailability, a pterostilbene nano-emulsion gel (PTN-NEG) formulation (0.1% and 0.2% w/w) was developed to enhance its therapeutic efficacy.
methodsPsoriasis was induced in C57BL/6J mice by applying IMQ (62.5 mg/day) on a 5 cm
resultsPTN-NEG restored antioxidant balance, reduced pro-inflammatory cytokines, inhibited NF-κB activation, and suppressed keratinocyte proliferation. It unregulated DUSP-1, modulating MAPK signaling and preventing psoriasis progression. PTN-NEG also improved epidermal structure, reduced hyperplasia, and prevented splenomegaly. Notably, PTN inhibited DNMT-1, suggesting a novel epigenetic mechanism for psoriasis.
conclusionTo our knowledge, this study is the first to demonstrate that PTN-NEG mitigates psoriasis through anti-inflammatory, antioxidant, and epigenetic regulatory mechanisms, highlighting its therapeutic potential in psoriasis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.